| Biomarker ID | 1708 |
| PMID | 26126436 |
| Year | 2015 |
| Biomarker | hsa-miR-4316 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue+Urine+Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa (Tissue, Serum, Urine) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathway include: synapse; nervous system development; Golgi apparatus; DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity |
| Experiment | Prostate Cancer Vs Benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | For training cohort 99 PCa with 51 controls were selected. Tissue, Urine and Serum all three samples were analysed |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Tissue: p<0.001; Urine: p=0.022 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Values in regulatation column are presented as median (interquartile range; × 102 copies/miRNA concentration) |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |